Skip to content
Sunday 9 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

pharmaceuticals

  • Covid-19, a year on: How Big Pharma reinvented itself

    March 25, 2021

    In this series, Morning Wire looks back at the last year of the pandemic and Covid restrictions and takes stock of its impact on industries and issues at the heart of British society. Read more: Read the full Covid-19, a year on series here. Six years ago, pharmaceutical chief executive Martin Shkreli drew international condemnation when his [...]

  • Rush hour in Israel as global interest in potential Covid-19 cure accelerates

    March 9, 2021

    Brazil’s foreign minister, Ernesto Araujo, arrived in Israel yesterday as his government is said to be highly interested in EXO-CD24, a new drug that has been hailed as a possible cure for Covid-19. Araujo, accompanied by Eduardo Bolsonaro, the son of Brazilian president Jair Bolsonaro, is reportedly keen to learn more about the treatment, which [...]

  • World’s first Covid-19 study where people are infected with virus to begin in London

    February 17, 2021

    World's first Covid-19 study, where people are injected with virus, begins in London

  • AstraZeneca gets vaccine boost as sales jump to nearly $26bn

    February 11, 2021

    Product sales at AstraZeneca jumped 10 per cent in 2020, up to nearly $26bn, in a year that made the at pharmaceutical company a household name. Total revenue at the business stood at $2.6bn, up nine per cent from 2019. Globally, new medicines represented 52 per cent of total revenue for the year. AstraZeneca’s share [...]

  • David Beckham-backed cannabis firm on course to become LSE’s first CBD listing

    February 4, 2021

    UK-based Cellular Goods is seeking a listing on the London Stock Exchange, which would make them the LSE’s first pure-play CBD business

  • Oxford University given £100m to launch fight against antibiotic resistance

    January 19, 2021

    The University of Oxford has been given £100m for a new institute focusing on resistance to antibiotics, one of the largest donations in its history. The gift will help combat the global issue of antimicrobial resistance (AMR), which is one of the world’s greatest healthcare challenges. The funding has been delivered by chemicals giant INEOS [...]

  • First psychedelic healthcare fund launches in Britain

    December 18, 2020

    Britain’s first investment fund dedicated solely to psychedelic healthcare launched this week, allowing investors to put money into mind altering drugs for medical use.  The fund, launched by London-based venture capital firm Neo Kuma, has an investment thesis focused on clinically proven psychedelic medicines that it believes will hit the market in the next five [...]

  • The new drug habits

    October 21, 2005

    Pharmaceutical companies are increasingly turning to biotechnology ventures to help them rescue their flagging profits. Investors are looking at biotechnology companies to reinvigorate a moribund drug industry in a way the big pharmaceutical giants have failed to do over the last two years. Observers say companies such as America’s Pfizer or Britain’s GlaxoSmithKline, known as [...]

  • Flu anti-virus causes 17% profit jump

    October 20, 2005

    Roche, the maker of bird flu anti-viral Tamiflu, yesterday announced a third quarter revenue increase of 17 per cent thanks to a jump in sales of the drug. The Swiss firm said sales of Tamiflu had more than doubled to SFr279m (£123m) and the companies overall sales for the quarter ending September climbed to SFr8.8bn. [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 18
  • Page 19
  • Page 20

Trending Articles

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • PwC’s Embankment HQ to get major makeover ahead of Canary Wharf move

  • Family feud: London estate agent Winkworth sues chair over plot with wife to oust son from board

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

  • A tribute to wine legend Matthew Jukes by his friend Libby Brodie

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook